FZX Stock Overview
A healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 3/6 |
| Dividends | 0/6 |
My Notes
Capture your thoughts, links and company narrative
Ainos, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$2.63 |
| 52 Week High | US$3.79 |
| 52 Week Low | US$2.49 |
| Beta | 1.45 |
| 1 Month Change | 0% |
| 3 Month Change | 1.20% |
| 1 Year Change | n/a |
| 3 Year Change | n/a |
| 5 Year Change | n/a |
| Change since IPO | 1,123.84% |
Recent News & Updates
Recent updates
Shareholder Returns
| FZX | DE Biotechs | DE Market | |
|---|---|---|---|
| 7D | 0% | 2.1% | 0.6% |
| 1Y | n/a | -13.8% | 7.2% |
Return vs Industry: Insufficient data to determine how FZX performed against the German Biotechs industry.
Return vs Market: Insufficient data to determine how FZX performed against the German Market.
Price Volatility
| FZX volatility | |
|---|---|
| FZX Average Weekly Movement | n/a |
| Biotechs Industry Average Movement | 7.1% |
| Market Average Movement | 4.9% |
| 10% most volatile stocks in DE Market | 11.7% |
| 10% least volatile stocks in DE Market | 2.4% |
Stable Share Price: FZX has not had significant price volatility in the past 3 months.
Volatility Over Time: Insufficient data to determine FZX's volatility change over the past year.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 1984 | 43 | Chun-Hsien Tsai | www.ainos.com |
Ainos, Inc., a healthcare company, engages in developing medical technologies for point-of-care testing and safe and novel medical treatment for disease indications. The company offers COVID-19 antigen rapid test kit and Ainos’ cloud-based test management App, a cloud-based test management platform comprising an antigen rapid test kit, a personal application, and an enterprise app; COVID-19 nucleic acid test; volatile organic compounds point-of-care testing; Very Low-Dose Oral Interferon Alpha, a low-dose oral interferon alpha formulation based IFN-a’s broad treatment applications; and Synthetic RNA developing a SRNA technology platform in Taiwan. It also provides women’s health, pneumonia, Ainos Pen, AI Nose, and other products.
Ainos, Inc. Fundamentals Summary
| FZX fundamental statistics | |
|---|---|
| Market cap | €8.94m |
| Earnings (TTM) | -€12.61m |
| Revenue (TTM) | €111.78k |
80.0x
P/S Ratio-0.7x
P/E RatioIs FZX overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| FZX income statement (TTM) | |
|---|---|
| Revenue | US$122.11k |
| Cost of Revenue | US$375.85k |
| Gross Profit | -US$253.73k |
| Other Expenses | US$13.52m |
| Earnings | -US$13.77m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
n/a
| Earnings per share (EPS) | -2.31 |
| Gross Margin | -207.79% |
| Net Profit Margin | -11,276.98% |
| Debt/Equity Ratio | 23.3% |
How did FZX perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2024/03/12 21:41 |
| End of Day Share Price | 2023/12/14 00:00 |
| Earnings | 2023/12/31 |
| Annual Earnings | 2023/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on .
Analyst Sources
Ainos, Inc. is covered by 0 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|